KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $434.2 million.

  • Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) rose 54.44% to $434.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.2 million, marking a year-over-year increase of 54.44%. This contributed to the annual value of $286.6 million for FY2024, which is 32.32% up from last year.
  • Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $434.2 million in Q3 2025, which was up 6.80% from $406.5 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $434.2 million in Q3 2025 and a low of $159.9 million during Q1 2021.
  • In the last 3 years, Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $237.7 million in 2024 and averaged $281.7 million.
  • Data for Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY soared of 71.31% (in 2025) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $169.0 million in 2021, then rose by 12.17% to $189.6 million in 2022, then climbed by 14.28% to $216.6 million in 2023, then spiked by 32.32% to $286.6 million in 2024, then skyrocketed by 54.44% to $434.2 million in 2025.
  • Its last three reported values are $434.2 million in Q3 2025, $406.5 million for Q2 2025, and $402.0 million during Q1 2025.